These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3825695)

  • 21. Sensorimotor disturbances in Parkinson's disease: index finger test.
    Chouza C; Scaramelli A; Aljanati R; De Medina O; Caamaño JL; Lorenzo J; Romero S
    Adv Neurol; 1987; 45():339-43. PubMed ID: 3825707
    [No Abstract]   [Full Text] [Related]  

  • 22. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
    Poewe W
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
    Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medical management and social status of elderly Parkinson patients].
    Vieregge P; Körtke D; Meyer-Bornsen C
    Z Gerontol; 1994; 27(4):260-9. PubMed ID: 7975817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinicopharmacological study of long-term Jumex + Dopaflex combination treatment in Parkinson's syndrome.
    Antóny M; Tóth G; Széplaki Z
    Ther Hung; 1982; 30(4):168-71. PubMed ID: 6821398
    [No Abstract]   [Full Text] [Related]  

  • 27. Motor response complications with chronic levodopa therapy.
    Chase TN; Fabbrini G; Juncos JL; Mouradian MM
    Adv Neurol; 1990; 53():377-81. PubMed ID: 2239478
    [No Abstract]   [Full Text] [Related]  

  • 28. Long-term follow-up of globus pallidus chronic stimulation in advanced Parkinson's disease.
    Durif F; Lemaire JJ; Debilly B; Dordain G
    Mov Disord; 2002 Jul; 17(4):803-7. PubMed ID: 12210880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levodopa-induced local cerebral blood flow changes in Parkinson's disease and related disorders.
    Kobari M; Fukuuchi Y; Shinohara T; Obara K; Nogawa S
    J Neurol Sci; 1995 Feb; 128(2):212-8. PubMed ID: 7738597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 31. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease.
    Syed N; Murphy J; Zimmerman T; Mark MH; Sage JI
    Mov Disord; 1998 Mar; 13(2):336-8. PubMed ID: 9539350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The treatment of Parkinson's disease.
    Godwin-Austen RB
    Postgrad Med J; 1977 Dec; 53(626):729-31. PubMed ID: 343079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment.
    Hausner RS
    J Clin Psychiatry; 1983 Jan; 44(1):13-6. PubMed ID: 6130081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CSF biopterin levels and clinical features of patients with juvenile parkinsonism.
    Furukawa Y; Nishi K; Kondo T; Mizuno Y; Narabayashi H
    Adv Neurol; 1993; 60():562-7. PubMed ID: 8420192
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of standard carbidopa-levodopa and sustained-release carbidopa-levodopa in Parkinson's disease: pharmacokinetic and quality-of-life measures.
    Pahwa R; Lyons K; McGuire D; Silverstein P; Zwiebel F; Robischon M; Koller WC
    Mov Disord; 1997 Sep; 12(5):677-81. PubMed ID: 9380047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Trial use of L-dopa associated with a dopa-decarboxylase inhibitor in Parkinson's syndrome].
    Carotti A; Tomassetti G; Lucciarini L; Barone G; Mugnai A
    Clin Ter; 1974 Jul; 70(1):9-15. PubMed ID: 4153252
    [No Abstract]   [Full Text] [Related]  

  • 37. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 39. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A case of levodopa-responsive camptocormia associated with advanced Parkinson's disease.
    Ho B; Prakash R; Morgan JC; Sethi KD
    Nat Clin Pract Neurol; 2007 Sep; 3(9):526-30. PubMed ID: 17805247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.